Protein expression patterns of matrix metalloproteinases (MMPs) were examined in mouse reproductive organs during estrous cycle. Estrous cycle was classified into diestrus, proestrus, estrus or metestus and MMP expression was analyzed by zymography using gelatin as a substrate. Uterine fluid (UF) obtained both at diestrus and proestrus exhibited 4 major MMPs including 106kDa, 64kDa, 62kDa and 59kDa gelatinases. However, in UF at estrus, the gelatinolytic activity of 64kDa MMP disappeared and that of 106kDa and 62kDa MMPs dramatically decreased. At metestrus, 64kDa MMP activity reappeared and 106kDa and 62kDa MMP exhibited increased activities such that the band intensity of 106kDa was comparable to that in UF at diestrus. Gelatinolytic activity of 59kDa MMP was not changed throughout the cycle. Both ovarian and oviductal tissue homogenate revealed 4 MMPs which corresponded to the 4 MMPs of UF. However, unlike UF MMPs, gelatinolytic activity of these MMPs did not show distinct changes throughout the cycle. Either an inhibitor of MMP, 1, 10-phenanthroline, or a metal chelator, EDTA, abolished the appearance of the above MMP activities in gelatinated gel whereas a serine proteinase inhibitor, phenylmethylsulfonyl fluoride, failed to inhibit the appearance of MMP activities, proving that gelatinolytic activity of the above reproductive tissues were due to the enzymatic activity of MMP. When gelatinolytic activity of mouse serum was examined, it revealed 5 MMPs (131kDa, 106kDa, 89kDa, 64kDa and 62kDa bands) and one gelatinase (84kDa) band. From these results, it is concluded that the protein expression of MMPs of mouse reproductive organs, particularly uterus, is temporally regulated during estrous cycle and uterine 106kDa, 64kDa and 62kDa MMP,3 are suggested to play an important role in cyclic tissue remodeling of mouse uterus.
Animals ; Diestrus ; Edetic Acid ; Estrous Cycle* ; Estrus ; Female ; Gelatin ; Gelatinases ; Matrix Metalloproteinases* ; Metestrus ; Mice* ; Oviducts ; Phenylmethylsulfonyl Fluoride ; Proestrus ; Serine Proteases ; Uterus

Every researcher wants their research to gain more recognition, and this desire is achieved by publishing their article in a journal with higher impact. It is very important to get researchers interested in the Journal of Korean Neurosurgical Society (JKNS). Therefore, the first goal was to promote the publication of papers in our journal. To do this, a table of contents was sent out, and the citation ranking was announced every 2 months. Several efforts have been made to publish good papers. Foreign speakers, who were invited to a conference hosted by the Korean Neurosurgical Society were contacted and politely requested to write a paper addressing their recent research. Domestic and international researchers highly renowned in their fields were also contacted to submit their novel works to our journal. The journal impact factor of our journal has continued to rise for the last 3 years and reached 1.376 in 2019. It can be said that the JKNS is now competitive with other international neurosurgery journals. These achievements were not due to the efforts of the editorial boards alone. This was because our society members have submitted very good papers, and because many of our members have cited the papers published in our journal. We believe that this will continue in the future. The next step of evolution of the JKNS has begun, and this is the beginning of another great development.

Every researcher wants their research to gain more recognition, and this desire is achieved by publishing their article in a journal with higher impact. It is very important to get researchers interested in the Journal of Korean Neurosurgical Society (JKNS). Therefore, the first goal was to promote the publication of papers in our journal. To do this, a table of contents was sent out, and the citation ranking was announced every 2 months. Several efforts have been made to publish good papers. Foreign speakers, who were invited to a conference hosted by the Korean Neurosurgical Society were contacted and politely requested to write a paper addressing their recent research. Domestic and international researchers highly renowned in their fields were also contacted to submit their novel works to our journal. The journal impact factor of our journal has continued to rise for the last 3 years and reached 1.376 in 2019. It can be said that the JKNS is now competitive with other international neurosurgery journals. These achievements were not due to the efforts of the editorial boards alone. This was because our society members have submitted very good papers, and because many of our members have cited the papers published in our journal. We believe that this will continue in the future. The next step of evolution of the JKNS has begun, and this is the beginning of another great development.

Objectives: The early growth response 3 (EGR3) gene located in chromosome 8p21.3 is one of the susceptibility loci in many psychiatric disorders. EGR3 gene plays critical roles in signal transduction in the brain, which is involved in neuronal plasticity, neuronal development, learning, memory, and circadian rhythms. Recent studies have suggested EGR3 as a potential susceptibility gene for bipolar disorder (BPD). However, this requires further replication with an independent sample set. Methods: To investigate the genetic role of EGR3 in Korean patients, we genotyped six single-nucleotide polymorphisms (SNPs) in the chromosome region of EGR3 in 1076 Korean BPD patients and 773 healthy control subjects. Results: Among the six examined SNPs of EGR3 (rs17088531, rs1996147, rs3750192, rs35201266, rs7009708, rs1008949), SNP rs35201266, rs7009708, rs1008949 showed a significant association with BPD (p = 0.0041 for rs35201266 and BPD2, p = 0.0074 for rs1008949 and BPD, p = 0.0052 for rs1008949 and BPD1), which withstand multiple testing correction. In addition, the ‘G-C-C-C’ and ‘G-C-G-C’ haplotypes of EGR3 were overrepresented in the patients with BPD (p = 0.0055, < 0.0001, respectively) and the ‘G-T-G-C’ haplotype of EGR3 was underrepresented in patients with BPD (p = 0.0040). Conclusions In summary, our study supports the association of EGR3 with BPD in Korean population sample, and EGR3 could be suggested as a compelling susceptibility gene in BPD.

No abstract available.
Ageusia* ; Humans ; Myasthenia Gravis* ; Thymoma

OBJECTIVES: It has been shown that early intervention is crucial for favorable outcome in patients with schizophrenia. However, development of biomarkers for predicting prognosis of psychotic disorder still requires more research. In this study, we aimed to investigate whether baseline mismatch negativity (MMN) predict prognosis in patients with first episode psychosis (FEP). METHODS: Twenty-four patients with FEP and matched healthy controls (HCs) were examined with MMN at baseline, and their clinical status were re-assessed after 1 year. Repeated-measures analysis of variance was performed to compare baseline MMN between the two groups. Multiple regression analysis was used to identify factors predicting prognosis in FEP patients during the follow-up period. RESULTS: MMN amplitudes at baseline were significantly reduced in patients with FEP compared to healthy controls. In the multiple regression analysis, baseline MMN amplitude significantly predicted later improvement of performances on digit span and delayed recall of California Verbal Learning Test. However, baseline MMN did not predicted improvement of clinical symptoms. CONCLUSION: These results indicate that MMN may be a possible predictor of improvement in cognitive functioning in patients with FEP. Future study with larger sample and longer follow-up period would be needed to confirm the findings of the current study.
Biomarkers ; California ; Cognition ; Early Intervention (Education) ; Follow-Up Studies* ; Humans ; Polytetrafluoroethylene ; Prognosis* ; Psychotic Disorders* ; Schizophrenia ; Verbal Learning

In schizophrenia, while antipsychotic medications are the primary treatment, auditory hallucinations may sometimes persist despite pharmacotherapy, and negative symptoms and cognitive impairments often show a limited response to these medications. Transcranial magnetic stimulation (TMS) has emerged as a promising adjunctive treatment, capable of modulating neuronal activity in targeted brain regions. Low-frequency repetitive TMS (rTMS) directed at the left temporoparietal cortex has demonstrated efficacy in reducing auditory hallucinations. In addressing negative symptoms, high-frequency rTMS applied to the dorsolateral prefrontal cortex has shown some effectiveness, though outcomes can vary. Innovative techniques, including theta burst stimulation and personalized approaches utilizing neuroimaging, are currently under investigation to further enhance the therapeutic potential of TMS. This review examines the application of TMS in the treatment of schizophrenia, emphasizing the necessity of ongoing research to refine and optimize its efficacy across diverse symptom domains.

In schizophrenia, while antipsychotic medications are the primary treatment, auditory hallucinations may sometimes persist despite pharmacotherapy, and negative symptoms and cognitive impairments often show a limited response to these medications. Transcranial magnetic stimulation (TMS) has emerged as a promising adjunctive treatment, capable of modulating neuronal activity in targeted brain regions. Low-frequency repetitive TMS (rTMS) directed at the left temporoparietal cortex has demonstrated efficacy in reducing auditory hallucinations. In addressing negative symptoms, high-frequency rTMS applied to the dorsolateral prefrontal cortex has shown some effectiveness, though outcomes can vary. Innovative techniques, including theta burst stimulation and personalized approaches utilizing neuroimaging, are currently under investigation to further enhance the therapeutic potential of TMS. This review examines the application of TMS in the treatment of schizophrenia, emphasizing the necessity of ongoing research to refine and optimize its efficacy across diverse symptom domains.

In schizophrenia, while antipsychotic medications are the primary treatment, auditory hallucinations may sometimes persist despite pharmacotherapy, and negative symptoms and cognitive impairments often show a limited response to these medications. Transcranial magnetic stimulation (TMS) has emerged as a promising adjunctive treatment, capable of modulating neuronal activity in targeted brain regions. Low-frequency repetitive TMS (rTMS) directed at the left temporoparietal cortex has demonstrated efficacy in reducing auditory hallucinations. In addressing negative symptoms, high-frequency rTMS applied to the dorsolateral prefrontal cortex has shown some effectiveness, though outcomes can vary. Innovative techniques, including theta burst stimulation and personalized approaches utilizing neuroimaging, are currently under investigation to further enhance the therapeutic potential of TMS. This review examines the application of TMS in the treatment of schizophrenia, emphasizing the necessity of ongoing research to refine and optimize its efficacy across diverse symptom domains.

In schizophrenia, while antipsychotic medications are the primary treatment, auditory hallucinations may sometimes persist despite pharmacotherapy, and negative symptoms and cognitive impairments often show a limited response to these medications. Transcranial magnetic stimulation (TMS) has emerged as a promising adjunctive treatment, capable of modulating neuronal activity in targeted brain regions. Low-frequency repetitive TMS (rTMS) directed at the left temporoparietal cortex has demonstrated efficacy in reducing auditory hallucinations. In addressing negative symptoms, high-frequency rTMS applied to the dorsolateral prefrontal cortex has shown some effectiveness, though outcomes can vary. Innovative techniques, including theta burst stimulation and personalized approaches utilizing neuroimaging, are currently under investigation to further enhance the therapeutic potential of TMS. This review examines the application of TMS in the treatment of schizophrenia, emphasizing the necessity of ongoing research to refine and optimize its efficacy across diverse symptom domains.